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ABSTRACT: The class III lysine deacylases (KDACs), also
known as the sirtuins, have emerged as interesting drug targets
for therapeutic intervention in a variety of diseases. To gain a
deeper understanding of the processes aﬀected by sirtuins, the
development of selective small molecule modulators of
individual isozymes has been a longstanding goal. Essential
for the discovery of novel modulators, however, are good
screening protocols and mechanistic insights with regard to the
targets in question. We therefore evaluated the activities of the seven human sirtuin hydrolases against a panel of ﬂuorogenic
substrates. Both commonly used, commercially available substrates and novel chemotypes designed to address recent
developments in the ﬁeld of lysine post-translational modiﬁcation were evaluated. Our investigations led to the discovery of two
new ﬂuorogenic ε-N-succinyllysine-containing substrates that enable highly eﬃcient and enzyme-economical screening
employing sirtuin 5 (SIRT5). Furthermore, optimized protocols for facile kinetic investigations were developed, which should be
valuable for enzyme kinetic investigations. Finally, these protocols were applied to a kinetic analysis of the inhibition of SIRT5 by
suramin, a potent sirtuin inhibitor previously shown by X-ray crystallography to bind the substrate pocket of the human SIRT5
KDAC enzyme.
■ INTRODUCTION
The sirtuins, silent information regulator 2 (Sir2) enzymes, are
a family of NAD-dependent KDACs comprising seven human
isoforms (SIRT1−7).1−4 These enzymes have been linked to a
variety of phenotypes and are therefore considered targets for
therapeutic intervention in a broad spectrum of diseases,
including various cancers, diabetes, cardiovascular disease, and
neurodegeneration.5−8 The human genome encodes for a total
of 18 diﬀerent KDACs, 11 of which are Zn2+-dependent
isoforms (classes I, II, and IV), while the sirtuins constitute the
class III KDACs (Figure 1a).1,2 Contrary to the Zn2+-
dependent isozymes, the sirtuins utilize NAD as a cofactor in
a deacylation event that has been studied mechanistically9−12 as
well as supported by several X-ray cocrystal structures with
substrates and/or cofactor bound to the enzyme13−17 (see
Figure 1b for overall reaction). Only sirtuins 1−3 and 5 have
been shown to harbor robust deacetylase activity, while sirtuins
6 and 7 were signiﬁcantly less active and SIRT4 showed no
activity.18,19 Sirtuin 4 has been shown to facilitate ADP-
ribosylation20 and has therefore been suggested to be an ADP-
ribosyl transferase enzyme rather than a deacetylase. Moreover,
SIRT5 was recently shown to be a potent demalonylase and
desuccinylase of lysine residues in mitochondrial proteins.21
The precise roles of the individual KDAC isoforms in cellular
function are not yet fully understood, however, and new tools
for accurate and eﬃcient proﬁling of their enzymatic activity are
therefore highly desirable. Furthermore, development of
protocols for high-throughput screening eﬀorts aimed at the
discovery of new inhibitor candidates is an important objective.
In light of the recent discovery of novel post-translational
acylations of lysine ε-amino groups,22 we envisioned that
performance of a systematic screening of the speciﬁcities of the
complete panel of recombinant human sirtuins 1−7 against a
series of ﬂuorogenic substrates accommodating variations in
both peptide sequence and identity of the ε-N-acyl group might
yield interesting new tools for some of these enzymes.
■ RESULTS AND DISCUSSION
Substrate Collection. For the proﬁling, we selected the
collection of substrates shown in Scheme 1a. Fluorogenic
peptide fragments 1−3 (based on p53 fragments), 5a (based on
a histone 4 fragment), and 6a are commercially available
substrates used for assays employing the various KDAC enzyme
isoforms. Substrate 4 was designed based on part of the amino
acid sequence of histone 3 (amino acids 6−9), and it was
included in our series because of work demonstrating activity of
SIRT6 against a H3K9Ac peptide in vitro23 (see Supporting
Information Scheme S1 for synthetic route). Substrates 5b, 5c,
6b, and 6c were designed and included in our panel to address
the recently discovered activities of SIRT5 against ε-N-
succinyllysine (Ksuc) and ε-N-malonyllysine (Kma) containing
substrates. Finally, we included a recently developed substrate
for eﬃcient proﬁling of class IIa KDACs (5d),24 as well as a
crotonylated peptide (5e) to address the recent discovery of ε-
N-crotonyllysine (Kcr) residues in histone tails.25
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The synthesis of substrate 5d has been reported previously;24
however, we were interested in devising an eﬃcient strategy
that would deliver 5a−e in a convergent manner from
inexpensive starting materials. As several attempts to introduce
the AMC ﬂuorophore at a late-stage failed, we applied the
protocol of Jung and co-workers26 followed by mild Fmoc
removal to prepare intermediate 8 in high yield. Subsequent
standard peptide coupling using DIC and HOBt as coupling
reagents and Boc group removal furnished peptide 10, which
could be readily functionalized to give substrates 5a−e
(Scheme 1b). The intermediate 8 was also used for preparation
of substrates 6b and 6c (Supporting Information Scheme S2).
Substrate Proﬁling with SIRT1−7. For comparison we
ﬁrst tested for deacylation using 1 μg of enzyme per reaction.
The deacylations were allowed to proceed for 1 h before adding
trypsin “developer” to release the ﬂuorophore of deacylated
substrate molecules and thereby obtain end point assay
readings (see Supporting Information Figure S1 for schematic
representation of the assay). Not surprisingly, on the basis of
the literature,19 SIRT1−3 generally exhibited good activities
toward the acetylated (Kac) substrates, whereas no measurable
activities were observed for sirtuins 4, 6, and 7 (Figure 2).
Sirtuin 5 exhibited poor activity against the Kac substrates in
our collection, with only a poor signal-to-background ratio
observed against substrate 2, which is somewhat surprising
because SIRT5 has been classiﬁed as an active deacetylase
enzyme.19 This, however, agrees with more recent inves-
tigations reporting low aﬃnity for Kac substrates with SIRT5.21
On the other hand, SIRT5 exhibited very eﬃcient desuccinylase
activity with substrate 5b, which is also in agreement with
recent contributions in the literature using nonﬂuorogenic
substrates.21,27 Unfortunately, substrate 4, which was designed
in the hopes of achieving activity of SIRT6, did not furnish a
measurable signal under the applied conditions. This indicates
that more elaborate H3K9Ac-containing fragments are
necessary in order to obtain SIRT6 deacetylase activity, as
the reported activity was observed with a ∼2700 Da H3
peptide.20 In addition, the reported activity was obtained with
>4 times the amount of enzyme used in the present study,
which would be considered a prohibitively large amount of
enzyme for screening purposes.
The activities of sirtuins 1−3 and 5 were then measured
against substrates 5a−c and 6a−c, which conﬁrmed a selective
demalonylase and desuccinylase activity of SIRT5, while
SIRT1−3 showed deacetylase activity exclusively (Figure 3).
The deacetylation reactions catalyzed by SIRT1 were
performed with two diﬀerent commercially available prepara-
tions of the enzyme to test whether this would inﬂuence the
substrate speciﬁcity. Thus, the six acetylated substrates were
treated with full-length SIRT1 enzyme28 or a truncated SIRT1-
GST fusion protein,29 respectively (Supporting Information
Figure S2). Under the applied conditions, the eﬃcacies of these
two diﬀerent enzymes followed the same general trend but with
higher activities observed for the full-length enzyme except
against substrate 4 where equally good activities were observed
(Supporting Information Figure S2).
Finally, the activities of SIRT1−3, SIRT5, and SIRT6 against
substrates 5d and 5e were recorded under the same conditions
as described vide supra. The very low activities observed against
substrate 5d are in agreement with previous ﬁndings.30
Decrotonylase activity was investigated brieﬂy using substrate
5e because of the very recent work showing that crotonylation
of ε-amino groups of lysine residues should now be considered
a possible post-translational modiﬁcation in histone proteins.25
A weak signal was observed for SIRT1, which may warrant
further investigations with more elaborate substrates in the
future, while a lack of activity was observed for sirtuins 2, 3, 5,
and 6 (Supporting Information Figure S3). As such, our results
do not indicate that sirtuins harbor potent decrotonylase
activity, albeit based on a limited data set.
Optimization of SIRT5 Desuccinylase Assays. Because
of the high eﬃcacy of SIRT5 observed against succinylated
substrates 5b and 6b (Figure 3), we envisioned that these
substrates might potentially prove useful for eﬃcient screening
of putative inhibitor compounds and decided to address these
substrates in further detail.31 First, we performed titrations to
determine appropriate amounts of enzyme necessary for SIRT5
screening with 5b or 6b, which showed that an enzyme loading
as low as 50 ng of SIRT5 per reaction (30 nM) was suﬃcient
for end point readings with both substrates (Supporting
Information Figure S4). Then kinetic constants were
determined by measuring initial rate velocities as a function
of substrate concentration and ﬁtting the data to the
Michaelis−Menten equation to give the Km and Vmax values
as shown in Table 1. The kcat values were calculated from the
relationship kcat = Vmax[enzyme]
−1, based on enzyme stock
concentration and purity given by the enzyme suppliers.
The turnover numbers (kcat) and catalytic eﬃciencies
(kcatKm
−1) obtained for both of these substrates were somewhat
lower than those reported for longer non-ﬂuorophore-
containing peptide sequences (about 5- to 50-fold).21 The
detection of a released ﬂuorophore, however, enables
signiﬁcantly higher signal sensitivity compared to HPLC-
based screening methods, thus enabling the low enzyme
loading of 30 nM, as compared to the 1 μM recently reported
for an HPLC-based assay.27 The ﬂuorometric method
furthermore allows for easy performance of continuous rate
experiments as long as an appropriate secondary enzyme is
chosen. The secondary enzyme in the assay, which serves to
Figure 1. (a) Sequence-based classiﬁcation of the human lysine
deacetylases. (b) Proposed overall mechanism of the NAD-dependent
lysine deacetylation of the active sirtuins 1−3. Complete details can be
found in the referenced literature.9−12,19
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release the ﬂuorophore after the initial deacylation reaction of
interest (Supporting Information Figure S1), must meet two
important demands to be a successful in situ developer enzyme.
First, it must be faster than the initial enzyme in order to
Scheme 1. (a) Structures of the Analyzed Substrates and (b) Synthesis of Substrates 5a−ea
aReagents and conditions: (a) POCl3 (3 equiv), pyridine (10.6 equiv), 7-amino-4-methylcoumarin (AMC, 1.15 equiv), THF, 0 °C → rt, 2.5 h
(quant).26 (b) Piperidine (1.1 equiv), MeCN, CH2Cl2, 0 °C→ rt, 24 h (88%). (c) Ac-Leu-Gly-OH (1.02 equiv), diisopropylcarbodiimide (DIC, 1.1
equiv), hydroxybenzotriazole (1.1 equiv), CH2Cl2, rt, 50 min (80%). (d) Triﬂuoroacetic acid−CH2Cl2 (1:9, v/v), rt, 30 min. (e) Ac2O (1.5 equiv), i-
Pr2NEt (6 equiv), CH2Cl2, MeCN, 0 °C → rt, 1 h (34%, two steps). (f) Succinic anhydride (1.7 equiv), i-Pr2NEt (6 equiv), CH2Cl2, rt, 55 min
(70%, 2 steps). (g) (1) Potassium methyl malonate (2 equiv), i-Pr2NEt (2.5 equiv), HATU (2 equiv), MeCN, 0 °C, 20 min; (2) LiOH (7.3 equiv),
THF−H2O, rt, 15 min (49%, 3 steps from 9). (h) Triﬂuoroacetic anhydride (9 equiv), i-Pr2NEt (14 equiv), CH2Cl2, 0 °C→ rt, 22 h (60% from 9).
(i) trans-Crotonic anhydride (1.8 equiv), i-Pr2NEt (6 equiv), CH2Cl2, rt, 10 min (59% from 9).
Figure 2. Results of sirtuin deacetylation and desuccinylation of
substrate 5b. The data were obtained as end point readings after
incubation for 1 h with each substrate at 37 °C and represent at least
two individual experiments performed in duplicate. The amount of
recombinant enzyme added to each reaction was 1 μg/50 μL as
determined from stock solution concentrations and purities given by
the suppliers (SIRT1-GST fusion protein was used as SIRT1 source).
The RFU values are normalized to control wells without sirtuin
enzyme present. See Supporting Information Figures S2 and S3 for
additional proﬁling data.
Figure 3. Bar graph for deacylation of substrates 5a−c and 6a−c. The
data were obtained as end point readings after incubation for 1 h with
each substrate at 37 °C and represent at least two individual
experiments performed in duplicate.
Table 1. Kinetic Parameters for SIRT5 Desuccinylation of
Fluorogenic Substrates 5b and 6ba
substrate Km (μM) Vmax (μM s
−1) kcat (s
−1) kcatKm
−1 (s−1 M−1)
5b 33 ± 1.8 1.9 × 10−3 3 × 10−2 9.2 × 102
6b 84 ± 22 5.6 × 10−4 9 × 10−3 1.1 × 102
aThe Km value for NAD measured with substrate 6b at 200 μM was
150 ± 45 μM. Michaelis−Menten plot is shown in Figure S5a.
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instantaneously process the intermediate product to give a
readout, and second, it is essential that the sirtuin enzyme will
not be degraded under the assay conditions because of the
inherent peptidase activity of the developer.
For the present protocol, we considered the Lys-C protease,
which has been used as a mild nondegrading option in HDAC
experiments,32,33 and trypsin, which is known from end point
assays to be very potent. Initial rate experiments for Lys-C at 4
milliunits of enzyme per reaction revealed a Vmax that was
considerably higher than those of SIRT5 against 5b and 6b,
indicating that Lys-C could be a useful option (Supporting
Information Figure S6). With trypsin our concern was the
possibility of premature inactivation of SIRT5 due to
degradation. At a ﬁnal concentration of 10 μg/mL of trypsin
in the assay, however, the rate increase in ﬂuorescence signal
was stable for recordings up to one hour (Supporting
Information Figure S7). Protocols were thus established for
end point assays, where interference of the developer enzyme is
absent, as well as for continuous assays employing two diﬀerent
in situ developer enzymes.
Evaluation of Inhibitors. Though substrate 6b furnished
slightly lower catalytic eﬃcacy than 5b, its simple chemical
structure and hence easy accessibility was appealing, and it was
therefore decided to perform inhibition experiments using
substrate 6b. Initially, IC50 values were determined by nonlinear
regression of dose−response data obtained by end point assays.
The selected sirtuin inhibitors were the SIRT1 inhibitor
sirtinol,34 the SIRT2 inhibitor AGK2,35 and suramin,36 a drug
used to treat sleeping sickness. The IC50 values were all in
agreement with previously published data obtained using an
HPLC-based assay27 (Figure 4a, top).
In an attempt to achieve binding aﬃnity by interaction of the
active site arginine (Arg-105, Figure 4b) with a carboxylic or
hydroxamic acid functionality, three known HDAC inhibitors
that are all in clinical use were tested as well (Figure 4a, bottom
panel). This proved fruitless with the simple structures tested
herein, although evidence that a carboxylic acid moiety may
contribute to the binding aﬃnity of SIRT5 inhibitors was
recently described for ε-N-thiosuccinyllysine-containing inhib-
itors,27 which were designed by analogy to ε-N-thioacetyllysine-
containing SIRT1 inhibitors.30,37,38
Because of previously reported assay artifacts related to
ﬂuorophore-containing substrates, which has come under
scrutiny with respect to activation of SIRT1,39−42 we performed
kinetic inhibition experiments using the continuous assay
methods discussed vide supra to further validate the developed
substrates and protocols. We chose the commercially available
inhibitor suramin, which conveniently has been cocrystallized
with SIRT5,14 for our kinetic studies.
First, we measured steady-state velocities from a titration of
substrate 6b at saturating NAD concentration and varying
concentrations of suramin to give a secondary double reciprocal
plot (Lineweaver−Burk plot)43 as shown in Supporting
Information Figure S8. Intersection of the lines with the y-
Figure 4. (a) Inhibitor structures and sirtuin 5 inhibition data using substrate 6b. Data are based on two individual assays performed in duplicate.
The values in parentheses were previously reported for inhibition of desuccinylation determined in an HPLC−MS based assay with nonﬂuorogenic
peptides.27 (b) Geometry of NAD and a succinyllysine-containing peptide cocrystallized with SIRT5 (PDB accession code, 3RIY).21
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axis at constant Vmax
−1 shows that the inhibitor is competitive
with respect to the ﬂuorogenic substrate (6b), which
gratifyingly agrees with the X-ray structure showing that
suramin binds to the acyllysine substrate pocket of the
enzyme.14 Next, we measured progression curves for SIRT5
desuccinylase activity in the presence of varying concentrations
of suramin using the two diﬀerent developer enzymes
discussed. When using Lys-C as the coupled secondary enzyme,
we observed a lag time of almost 30 min before the system
reached a steady state. On the other hand, the resulting
progress curves remained linear up to 2 h (Figure 5a). Trypsin
development allowed for the system to reach steady state after
just 5−10 min, giving rise to linear curves up to at least 50 min
(Figure 5b). Linear graphs in these plots represent a constant
increase in the ﬂuorescence signal, which in turn reﬂects a
constant turnover rate of the SIRT5 enzyme in agreement with
a fast-on−fast-oﬀ mode of inhibition. Finally, ﬁtting the data to
eq 1, which is in accord with the fast-on−fast-oﬀ mechanism,
furnished similar Ki values regardless of the developer enzyme
used (Figure 5c). To our knowledge, these ﬁndings conclude
the ﬁrst disclosure of a kinetic investigation of SIRT5 inhibition
using the progression curve method.
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■ CONCLUSIONS
In summary, we have evaluated the activities of the seven
human sirtuin hydrolases against a series of ﬂuorogenic
substrates in vitro. The tested substrate collection was designed
to address enzyme speciﬁcities toward the most commonly
used commercial substrates as well as the recently discovered
lysine post-translational modiﬁcations (i.e., Kma, Ksuc, and
Kcr).22 Convergent synthetic routes for preparation of these
new chemotypes were devised to gain easy access to the
substrate collection.
Our screening conﬁrmed that SIRT1−3 all exhibit relatively
broad-spectrum deacetylase activities. Sirtuins 4, 6, and 7 were
practically inactive under our conditions, which is in agreement
with previous literature reporting lack of SIRT4 activity and
signiﬁcantly lower deacetylase activities of SIRT6 and SIRT7
compared to SIRT1−3.18 These ﬁndings, however, do not rule
out that these enzymes may deacylate substrates not yet
discovered. Sirtuin 5, on the other hand, exhibited somewhat
surprisingly low deacetylase activities but very potent
demalonylase and desuccinylase activities as recently described
for nonﬂuorogenic peptide substrates.
Thus, two new substrates were discovered, which enable
highly eﬃcient SIRT5 desuccinylation activity at signiﬁcantly
lower enzyme loading than previously described. As such, these
readily prepared substrates should be suitable for screening
eﬀorts toward the discovery of novel SIRT5 inhibitor
compounds. Furthermore, optimized conditions for facile
kinetic investigations of SIRT5 interaction with substrates
and/or inhibitors were developed, which will be valuable for
mechanistic investigations. The well-known inhibitor suramin,
which has been cocrystallized with SIRT5, was used to validate
our two diﬀerent continuous assay protocols by performing
progression curve experiments.
Additionally, the results of the ﬁrst decrotonylation experi-
ments performed with sirtuin enzymes indicated that sirtuins
are not likely to be potent decrotonylases.
■ EXPERIMENTAL METHODS
Materials. Recombinant SIRT1-GST fusion protein, SIRT2, and
Lys-C (Lysobacter enzymogenes) were purchased from Merck-Millipore
(Darmstadt, Germany), and SIRT1 (full length His-tagged), SIRT3,
SIRT5, and SIRT6 were from Enzo Life Sciences (Postfach,
Switzerland). Recombinant SIRT4 and SIRT7 were from Abnova
(Taipei, Taiwan). Sirtuin assay buﬀer was prepared as described in the
Biomol International product sheets BML-AK-555 [Tris-Cl (50 mM),
NaCl (137 μM), KCl (2.7 μM), MgCl2 (1 μM), pH 8.0, and bovine
serum albumin (1 mg/mL)]. The SIRT2 substrate (3), suramin,
sirtinol, and AGK2 inhibitors were from Enzo Life Sciences (Postfach,
Switzerland). 4-Phenylbutyric acid, valproic acid, NAD, and trypsin
(10 000 units/mg, TPCK treated from bovine pancreas) were from
Sigma-Aldrich (Steinheim, Germany).
Sirtuin Deacylation Assays. In brief, all reactions were performed
in black low binding NUNC 96-well microtiter plates. End point
assays were performed by incubation of the appropriate substrate,
NAD, sirtuin, and inhibitor (if applicable) in assay buﬀer (50 μL ﬁnal
volume). Control wells without enzyme were included in each plate.
After 1 h at 37 °C, a developer mixture (50 μL) containing
nicotinamide (2 mM) and trypsin (0.4 mg mL−1) was added, and the
assay was incubated for 15−30 min at room temperature before the
Figure 5. (a) Progress curves for enzyme inhibition of suramin against SIRT5 using substrate 6b and Lys-C as the secondary enzyme (linear
regression lines for the 30−120 min regions are shown in black). (b) Progress curves for suramin inhibition of SIRT5 using substrate 6b and trypsin
as developer (linear regression lines for the 10−50 min regions are shown in black). (c) Nonlinear ﬁtting of the data to eq 133,44 using the GraphPad
Prism software.
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plates were analyzed using a Perkin-Elmer Enspire plate reader with
excitation at 360 nm and emission at 460 nm. Rate experiments for
determination of kinetic parameters were performed by incubation of
substrate, NAD, and sirtuin in assay buﬀer (100 μL ﬁnal volume) with
in situ ﬂuorophore cleavage by Lys-C or trypsin. Fluorescence readings
were recorded every 30 s for at least 30 min at 25 °C to obtain initial
linear rates ν0 (RFU min
−1) for each concentration. The data were
analyzed using GraphPad Prism to aﬀord Km (μM) and Vmax (RFU
min−1) values. The kcat values were calculated based on the [7-amino-
4-methylcoumarin]−RFU standard curve (Supporting Information
Figure S5) and the enzyme purities and concentrations given by the
suppliers. The dilution series for dose−response inhibitor experiments
were prepared in SIRT assay buﬀer from DMSO stock solutions.
Substrate 6b was used for inhibition experiments, and the SIRT5
enzyme concentration was 50 ng/well (∼30 nM in 50 μL ﬁnal
volume) for end point assays or 200 ng/well (∼60 nM in 100 μL ﬁnal
volume) for continuous assays.
Chemistry. General Methods and Materials. 2-Chlorotrityl
chloride resin was from Sigma-Aldrich (Milwaukee, WI). All α-amino
acids, chemicals, and solvents were analytical grade and used without
further puriﬁcation as obtained from commercial suppliers. Anhydrous
THF was stored over sodium and freshly distilled prior to use.
Anhydrous MeCN was dried by storage over 3 Å molecular sieves.
Anhydrous CH2Cl2, i-Pr2NEt, and pyridine were dried by storage over
activated 4 Å molecular sieves. Dry column vacuum chromatography
was performed on silica gel 60 (particle size 0.015−0.040 mm).
Preparative reversed-phase HPLC was performed on a [250 mm × 20
mm, C18(2) Phenomenex Luna column (5 μm, 100 Å)] using an
Agilent 1260 LC system equipped with a diode array UV detector and
an evaporative light scattering (ELS) detector. A gradient with eluent
A (95:5:0.1, water−MeCN−TFA) and eluent B (0.1% TFA in
acetonitrile) rising linearly from 0% to 95% of B during t = 5−45 min
was applied at a ﬂow rate of 20 mL/min. The isolated substrates were
lyophilized from the HPLC solvents and stored at −20 °C. UPLC−
MS analyses were performed on a Waters Acquity ultrahigh
performance liquid chromatography system to conﬁrm purities of
>95% of all compounds, and high resolution mass spectroscopic
measurements were performed using ultrahigh performance liquid
chromatography−high resolution mass spectrometry (UHPLC-
HRMS) on a maXis G3 quadrupole time-of-ﬂight (TOF) mass
spectrometer (Bruker Daltonics, Bremen, Germany) equipped with an
electrospray (ESI) source. NMR spectra were recorded on a Varian
Mercury 300 instrument. 1H NMR, 13C NMR, and 19F NMR were
recorded at 300, 75, and 282 MHz, respectively. Chemical shifts are
reported in ppm relative to deuterated solvent peaks as internal
standards (δH, DMSO-d6 2.50 ppm; δC, DMSO-d6 39.52 ppm) or
external calibration (δF). Coupling constants (J) are given in hertz
(Hz). Multiplicities of 1H NMR signals are reported as follows: s,
singlet; d, doublet; dd, doublet of doublets; t, triplet; q, quartet; p,
pentet; m, multiplet; br, broad signal. Protons that were exchangeable
upon addition of D2O are denoted “ex”. Assignments of NMR spectra
are based on correlation spectroscopy (COSY, HSQC, HMQC, and/
or HMBC spectra).
Ac-Leu-Gly-Lys(Ac)-(7-amino-4-methylcoumarin) (5a).45
Crude Ac-Leu-Gly-Lys-(7-amino-4-methylcoumarin) triﬂuoroacetate
salt (10, 49 mg) was suspended in anhydrous CH2Cl2 (4 mL) and
anhydrous MeCN (3 mL) at 0 °C under N2. Hünig's base (63 mg, 488
μmol) and Ac2O (12 mg, 115 μmol) were added. After being stirred
for 1 h at room temperature, the reaction mixture was taken up in
brine. The aqueous phase was extracted with CH2Cl2 (3 × 20 mL),
and the combined organic phase was washed with aqueous HCl (1 M,
2 × 10 mL). The acidic aqueous phase was back-extracted with
CH2Cl2 (3 × 20 mL), then 10% MeOH in CH2Cl2 (5 × 20 mL). The
combined organic phase was then washed with saturated aqueous
NaHCO3 (10 mL) and the aqueous phase back-extracted with CH2Cl2
(3 × 20 mL). The combined organic phase was dried over MgSO4,
ﬁltered, and evaporated to dryness. Preparative reversed-phase HPLC
puriﬁcation of the crude residue aﬀorded 5a as a white ﬂuﬀy material
after lyophilization (13 mg, 34% from 9). Full characterization details
were not given in the original report and are therefore included here.45
1H NMR (DMSO-d6) δ = 10.39 (s, 1H, NHAMC), 8.34 (t, J = 5.8, 1H,
NHGly), 8.11 (d, J = 7.2, 1H, NHLeu), 8.02 (d, J = 7.5, 1H, NHα,Lys),
7.81 (t, J = 5.5, NHε,Lys), 7.80 (d, J = 2.0, 1H, H8AMC), 7.73 (d, J = 8.7,
1H, H5AMC), 7.52 (dd, J = 8.7 and 2.0, 1H, H6AMC), 6.27 (d, J = 1.4,
1H, H3AMC), 4.32−4.41 (m, 1H, Hα,Lys), 4.21 (q, J = 7.4, 1H, Hα,Leu),
3.74 (mABX,A, J = 16.8 and 5.7, 1H, Hα,Gly,A), 3.71 (mABX,B, J = 16.8 and
5.9, 1H, Hα,Gly,B), 3.00 (q, J = 6.1, 2H, CH2,ε,Lys), 2.40 (d, J = 1.3, 3H,
CH3,AMC), 1.84 (s, 3H, CH3CONHLeu), 1.77 (s, 3H, CH3CONHε,Lys),
1.51−1.74 (m, 3H, CHγ,Leu and CH2,β,Lys), 1.16−1.50 (m, 6H,
CH2,β,Leu, CH2,γ,Lys,CH2,δ,Lys), 0.88 (d, J = 6.5, 3H, CH3,Leu,A), 0.83
(d, J = 6.5, 3H, CH3,Leu,B).
13C NMR (DMSO-d6) δ = 172.9 (COLeu),
171.4 (COLys), 169.7 (CONHLeu), 169.02 (COGly/CONHε,Lys), 168.96
(COGly/CONHε,Lys), 160.0 (C2AMC), 153.6 (C8aAMC), 153.1 (C4AMC),
142.1 (C7AMC), 126.0 (C5AMC), 115.3 (C6AMC), 115.2 (C4aAMC),
112.4 (C3AMC), 105.8 (C8AMC), 53.6 (Cα,Lys), 51.5 (Cα,Leu), 42.0
(Cα,Gly), 40.5 (Cβ,Leu), 38.3 (Cε,Lys), 31.4 (Cβ,Lys), 28.9 (Cδ,Lys), 24.2
(Cγ,Leu), 22.9 (CH3,Leu,A), 22.6 (Cγ,Lys), 22.5 (CH3CO), 21.7
(CH3,Leu,B), 18.0 (CH3,AMC). UPLC−MS tR = 1.49 min, m/z 558.3
([M + H]+, C28H40N5O7
+ calcd 558.3). HRMS m/z 558.2916 ([M +
H]+, C28H40N5O7
+ calcd 558.2922).
Ac-Leu-Gly-Lys(succinyl)-(7-amino-4-methylcoumarin) (5b).
Crude Ac-Leu-Gly-Lys-(7-amino-4-methylcoumarin) triﬂuoroacetate
salt (10, 50 mg) was suspended in anhydrous CH2Cl2 (2 mL) and i-
Pr2NEt (0.1 mL) under N2 at room temperature. Succinic anhydride
(13 mg, 133 μmol) was added, immediately resulting in a clear
solution. After being stirred for 55 min, the reaction mixture was
evaporated to dryness. Preparative reversed-phase HPLC puriﬁcation
of the crude residue aﬀorded Ac-Leu-Gly-Lys(succinyl)-(7-amino-4-
methylcoumarin) (5b) as a white ﬂuﬀy material after lyophilization
(29 mg, 70% from 9). 1H NMR (DMSO-d6) δ 10.38 (s, 1H, NHAMC),
8.35 (t, J = 5.8, 1H, NHGly), 8.11 (d, J = 7.3, 1H, NHLeu), 8.02 (d, J =
7.5, 1H, NHα,Lys), 7.83 (t, J = 5.5, 1H, NHε,Lys), 7.80 (d, J = 2.0, 1H,
H8AMC), 7.72 (d, J = 8.7, 1H, H5AMC), 7.52 (dd, J = 8.7, 2.0, 1H,
H6AMC), 6.27 (d, J = 1.2, 1H, H3AMC), 4.32−4.42 (m, 1H, Hα,Lys), 4.22
(q, J = 7.4, 1H, Hα,Leu), 3.74 (mABX,A, J = 16.7 and 5.5, 1H, Hα,Gly,A),
3.71 (mABX,B, J = 16.7, 5.8, 1H, Hα,Gly,B), 3.01 (q, J = 6.3, 2H, CH2,ε,Lys),
2.34−2.42 (m, 5H, CH3,AMC, HO2CCH2), 2.23−2.32 (m, 2H,
CH2CONHε,Lys), 1.84 (s, 3H, CH3CONHLeu), 1.51−1.77 (m, 3H,
CHγ,Leu, CH2,β,Lys), 1.18−1.51 (m, 6H, CH2,β,Leu,CH2,γ,Lys,CH2,δ,Lys),
0.88 (d, J = 6.5, 3H, CH3,Leu,A), 0.83 (d, J = 6.4, 3H, CH3,Leu,B).
13C
NMR (DMSO-d6) δ 173.9 (CO2H), 173.0 (COLeu), 171.5 (COLys),
170.8 (NHε,LysCO), 169.8 (CH3CO), 169.0 (COGly), 160.1 (C2AMC),
153.7 (C8aAMC), 153.1 (C4AMC), 142.2 (C7AMC), 126.0 (C5AMC),
115.3 (C6AMC), 115.2 (C4aAMC), 112.4 (C3AMC), 105.8 (C8AMC), 53.6
(Cα,Lys), 51.5 (Cα,Leu), 42.1 (Cα,Gly), 40.5 (Cβ,Leu), 38.4 (Cε,Lys), 31.4
(Cβ,Lys), 30.0 (CH2CONHε,Lys), 29.2 (HO2CCH2), 28.8 (Cδ,Lys), 24.2
(Cγ,Leu), 23.0 (CH3,Leu,A), 22.9 (Cγ,Lys), 22.5 (CH3CO), 21.7
(CH3,Leu,B), 18.0 (CH3,AMC). UPLC−MS tR = 1.47 min, m/z 616.5
([M + H]+, C30H42N5O9
+ calcd 616.3). HRMS m/z 616.2976 ([M +
H]+, C30H42N5O9
+ calcd 616.2977).
Ac-Leu-Gly-Lys(malonyl)-(7-amino-4-methylcoumarin) (5c).
Potassium monomethyl malonate (50 mg, 0.319 mmol) was
suspended in MeCN (2 mL) and i-Pr2NEt (0.07 mL) under Ar at 0
°C. HATU (122 mg, 0.321 mmol) was added aﬀording a yellow
solution. After preincubation for 5 min, the crude Ac-Leu-Gly-Lys-(7-
amino-4-methylcoumarin) triﬂuoroacetate salt (10, 99 mg) was added,
and the resulting suspension was stirred at 0 °C. After the mixture was
stirred for 20 min, MeOH (1 mL) was added, and the reaction mixture
was evaporated to dryness. The resulting residue was puriﬁed by
column chromatography (0−8% MeOH in CH2Cl2), to aﬀord a white
foam [Ac-Leu-Gly-Lys((methyl)malonyl)-(7-amino-4-methylcoumar-
in) (84 mg). UPLC−MS tR = 1.56 min, m/z 616.3 ([M + H]+,
C30H42N5O9
+ calcd 616.3)]. This crude material was dissolved in THF
(1.0 mL) and aqueous LiOH (1.0 M, 1.0 mL). After being stirred for
15 min, the reaction mixture was concentrated to approximately 1 mL,
then neutralized by addition of aqueous HCl (2 M, 0.3 mL). The
resulting solution was puriﬁed by preparative reversed-phase HPLC to
aﬀord Ac-Leu-Gly-Lys(malonyl)-(7-amino-4-methylcoumarin) (5c) as
a white ﬂuﬀy material after lyophilization (40 mg, 49% from 9). 1H
NMR (DMSO-d6) δ = 10.39 (s, 1H, NHAMC), 8.35 (t, J = 5.8, 1H,
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NHGly), 8.11 (d, J = 7.2, 1H, NHLeu), 7.99−8.08 (m, 2H, NHα,Lys and
NHε,Lys), 7.80 (d, J = 1.9, 1H, H8AMC), 7.72 (d, J = 8.7, 1H, H5AMC),
7.52 (dd, J = 8.7 and 2.0, 1H, H6AMC), 6.27 (d, J = 1.2, 1H, H3AMC),
4.32−4.43 (m, 1H, Hα,Lys), 4.22 (q, J = 7.4, 1H, Hα,Leu), 3.74 (mABX,A, J
= 16.6 and 5.7, 1H, Hα,Gly,A), 3.71 (mABX,B, J = 16.6 and 5.6, 1H,
Hα,Gly,B), 3.10 (s, 2H, CH2(CO)2), 3.04 (q, J = 6.5, 2H, CH2,ε,Lys), 2.39
(d, J = 1.2, 3H, CH3,AMC), 1.84 (s, 3H, CH3CO), 1.51−1.79 (m, 3H,
CHγ,Leu and CH2,β,Lys), 1.19−1.51 (m, 6H, CH2,β,Leu, CH2,γ,Lys, and
CH2,δ,Lys), 0.88 (d, J = 6.5, 3H, CH3,Leu,A), 0.83 (d, J = 6.4, 3H,
CH3,Leu,B).
13C NMR (DMSO-d6) δ = 173.0 (COLeu), 171.5 (COLys),
169.8 (CH3CO), 169.6 (CO2H), 169.1 (COGly), 165.6 (CONHε,Lys),
160.1 (C2AMC), 153.7 (C8aAMC), 153.1 (C4AMC), 142.2 (C7AMC),
126.0 (C5AMC), 115.3 (C6AMC), 115.2 (C4aAMC), 112.4 (C3AMC),
105.8 (C8AMC), 53.6 (Cα,Lys), 51.5 (Cα,Leu), 42.6 (CH2(CO)2), 42.1
(Cα,Gly), 31.4 (Cβ,Lys), 28.7 (Cδ,Lys), 24.2 (Cγ,Leu), 23.0 (CH3,Leu,A), 22.9
(Cγ,Lys), 22.5 (CH3CO), 21.7 (CH3,Leu,B), 18.0 (CH3,AMC). UPLC−MS
tR = 1.49 min, m/z 602.3 ([M + H]
+, C29H40N5O9
+ calcd 602.3).
HRMS m/z 602.2823 ([M + H]+, C29H40N5O9
+ calcd 602.2821).
Ac-Leu-Gly-Lys(Tfa)-(7-amino-4-methylcoumarin) (5d).24
Crude Ac-Leu-Gly-Lys-(7-amino-4-methylcoumarin) triﬂuoroacetate
salt (10, 52 mg) was suspended in anhydrous CH2Cl2 (4 mL) and
MeCN (3 mL) under N2 at 0 °C. i-Pr2NEt (62 mg, 477 μmol) and
(CF3CO)2O (33 mg, 159 μmol) were added, and the mixture was
stirred for 100 min. Additional portions of i-Pr2NEt (100 μL, 0.58
mmol) and (CF3CO)2O (127 mg, 0.61 mmol) were added over a time
course of 20 h to drive the reaction to completion. Then the reaction
mixture was taken up in aqueous HCl (1 M, 10 mL) and CH2Cl2 (20
mL). The aqueous phase was extracted with CH2Cl2 (3 × 20 mL), and
the combined organic phase was washed with aqueous HCl (1 M, 10
mL), after which the aqueous phase was back-extracted with CH2Cl2
(3 × 20 mL). The organic phase was then washed with saturated
aqueous NaHCO3 (10 mL), dried over MgSO4, ﬁltered, and
evaporated to dryness. The resulting residue was puriﬁed by column
chromatography (0−5% MeOH in CH2Cl2), aﬀording the desired Ac-
Leu-Gly-Lys(Tfa)-(7-amino-4-methylcoumarin) (5d) as a white solid
(26 mg, 60% from 9). The 13C NMR data did not correspond fully
with previously reported data, since we did not observe additional
peaks attributed to a mixture of conformers.24 1H NMR (DMSO-d6) δ
= 10.39 (s, 1H, NHAMC), 9.42 (t, J = 5.7, 1H, NHCOCF3), 8.34 (t, J =
5.8, 1H, NHGly), 8.10 (d, J = 7.3, 1H, NHLeu), 8.05 (d, J = 7.5, 1H,
NHLys), 7.79 (d, J = 2.0, 1H, H8AMC), 7.72 (d, J = 8.7, 1H, H5AMC),
7.51 (dd, J = 8.7 and 2.0, 1H, H6AMC), 6.27 (d, J = 1.4, 1H, H3AMC),
4.32−4.44 (m, 1H, Hα,Lys), 4.22 (q, J = 7.5, 1H, Hα,Leu), 3.74 (mABX,A, J
= 16.8 and 5.4, 1H, Hα,Gly,A), 3.71 (mABX,B, J = 16.8 and 5.7, 1H,
Hα,Gly,B), 3.16 (q, J = 6.7, 2H, CH2,ε,Lys), 2.40 (d, J = 1.4, 3H,
CH3,AMC), 1.84 (s, 3H, CH3CONHLeu), 1.19−1.80 (m, 9H, CH2,β,Leu,
CHγ,Leu, CH2,β,Lys, CH2,γ,Lys, and CH2,δ,Lys), 0.88 (d, J = 6.5, 3H,
CH3,Leu,A), 0.83 (d, J = 6.4, 3H, CH3,Leu,B).
13C NMR (DMSO-d6) δ =
172.9 (COLeu), 171.4 (COLys), 169.7 (CH3CO), 169.0 (COGly), 160.0
(C2AMC), 156.1 (q, J = 35.9, COCF3), 153.6 (C8aAMC), 153.1
(C4AMC), 142.1 (C7AMC), 126.0 (C5AMC), 116.0 (q, J = 288.0, CF3),
115.3 (C6AMC), 115.2 (C4aAMC), 112.4 (C3AMC), 105.8 (C8AMC), 53.5
(Cα,Lys), 51.5 (Cα,Leu), 42.0 (Cα,Gly), 40.5 (Cβ,Leu), 39.0 (Cε,Lys), 31.3
(Cβ,Lys), 28.0 (Cδ,Lys), 24.2 (Cγ,Leu), 22.9 (CH3,Leu,A), 22.7 (Cγ,Lys), 22.5
(CH3CO), 21.6 (CH3,Leu,B), 18.0 (CH3,AMC).
19F NMR (DMSO-d6) δ
= −75.7 (CF3). UPLC−MS tR = 1.77 min, m/z 612.4 ([M + H]+,
C28H37F3N5O7
+ calcd 612.3). HRMS m/z 612.2646 ([M + H]+,
C28H37F3N5O7
+ calcd 612.2640).
Ac-Leu-Gly-Lys(crotonyl)-(7-amino-4-methylcoumarin) (5e).
Crotonoic acid (5.03 g, 58.4 mmol) was suspended in CH2Cl2 (50
mL) under N2, and the mixture was stirred at 0 °C. DIC (6.0 mL, 38.7
mmol) was added portionwise. The reaction mixture was stirred for 3
days and then evaporated to dryness. The resulting residue was taken
up in heptane (50 mL), and the white precipitate was ﬁltered oﬀ and
washed with heptane (3 × 10 mL). The combined organic phases were
evaporated to dryness to aﬀord crude trans-crotonic anhydride, which
was used directly in the acylation step. Crude Ac-Leu-Gly-Lys-(7-
amino-4-methylcoumarin) triﬂuoroacetate salt (10, 50 mg) was
suspended in anhydrous CH2Cl2 (2.5 mL) and i-Pr2NEt (0.1 mL)
under N2 at room temperature. Crotonyl anhydride (22 mg, 143
μmol) was added, resulting in a clear solution after stirring for 30 s.
The reaction mixture was stirred for 10 min and was then evaporated
to dryness. The resulting crude was puriﬁed by preparative reversed-
phase HPLC to aﬀord the title compound as a white ﬂuﬀy material
after lyophilization (24 mg, 59% from 9). 1H NMR (DMSO-d6) δ =
10.38 (s, 1H, NHAMC), 8.34 (t, J = 5.8, 1H, NHGly), 8.11 (d, J = 7.3,
1H, NHLeu), 8.03 (d, J = 7.5, 1H, NHLys), 7.85 (t, J = 5.6, 1H, NHε,Lys),
7.79 (d, J = 2.0, 1H, H8AMC), 7.72 (d, J = 8.7, 1H, H5AMC), 7.52 (dd, J
= 8.7 and 2.0, 1H, H6AMC), 6.56 (dq, J = 15.3 and 6.9, 1H, CH
CHCH3), 6.27 (d, J = 1.4, 1H, H3AMC), 5.86 (dq, J = 15.3 and 1.6, 1H,
CHCHCH3), 4.30−4.42 (m, 1H, Hα,Lys), 4.22 (q, J = 7.4, 1H,
Hα,Leu), 3.74 (mABX,A, J = 16.9 and 5.4, 1H, Hα,Gly,A), 3.71 (mABX,B, J =
16.9 and 6.1, 1H, Hα,Gly,B), 3.08 (q, J = 6.4, 2H, CH2,ε,Lys), 2.39 (d, J =
1.3, 3H, CH3,AMC), 1.84 (s, 3H, CH3CONHLeu), 1.75 (dd, J = 6.9 and
1.6, 3H, CHCHCH3), 1.51−1.72 (m, 3H, CHγ,Leu and CH2,β,Lys),
1.17−1.51 (m, 6H, CH2,β,Leu, CH2,γ,Lys, and CH2,δ,Lys), 0.88 (d, J = 6.5,
3H, CH3,Leu,A), 0.83 (d, J = 6.4, 3H, CH3,Leu,B).
13C NMR (DMSO-d6)
δ = 172.9 (COLeu), 171.4 (COLys), 169.7 (CH3CO), 169.0 (COGly),
164.8 (NHCOε,Lys), 160.0 (C2AMC), 153.6 (C8aAMC), 153.1 (C4AMC),
142.1 (C7AMC), 137.3 (CHCHCH3), 126.0 (C5AMC,CHCHCH3),
115.3 (C6AMC), 115.2 (C4aAMC), 112.4 (C3AMC), 105.8 (C8AMC), 53.6
(Cα,Lys), 51.5 (Cα,Leu), 42.0 (Cα,Gly), 40.5 (Cβ,Leu), 39.0 (Cε,Lys), 31.4
(Cβ,Lys), 28.9 (Cδ,Lys), 24.2 (Cγ,Leu), 23.0 (CH3,Leu,A), 22.9 (Cγ,Lys), 22.5
(CH3CO), 21.7 (CH3,Leu,B), 18.0 (CH3,AMC), 17.3 (CHCHCH3).
UPLC−MS tR = 1.62 min, m/z 584.4 ([M + H]+, C30H42N5O7+ calcd
584.3). HRMS m/z 584.3079 ([M + H]+, C30H42N5O7
+ calcd
584.3079).
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